Patient-Centred Care When Treating Plaque Psoriasis With Secukinumab: Reasons for Discontinuing Treatment Outside of Randomized Controlled Trials

Abstract

Keywords

secukinumab IL-17A plaque psoriasis discontinuation efficacy adverse event

Get full access to this article

View all access options for this article.

References

Langley

Elewski

Lebwohl

et al . Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.

Blauvelt

Prinz

Gottlieb

et al . Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484-493.

Torres

Puig

. Treatment goals for psoriasis: Should PASI 90 become the standard of care? Actas Dermosifiliografikas. 2015;106(3):155-157.

Doshi

Takeshita

Pinto

et al . Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057-1065.e4.